A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Rhee CK, Lee SH, Kim JS, Kim SJ, Kim SC, Kim YK, Kang HH, Yoon HK, Song JS, Moon HS, Kim JW, Kim CH, Shim BY, Kim HK, Sun DS, Kim KH.
Rhee CK, et al. Among authors: lee sh.
Lung Cancer. 2011 Apr;72(1):64-7. doi: 10.1016/j.lungcan.2010.07.003. Epub 2010 Sep 15.
Lung Cancer. 2011.
PMID: 20832894
Clinical Trial.